A randomized, non-blinded, 24-week pilot study to evaluate the effect of dapagliflozin (10 mg once daily) plus exenatide (2.0 mg once weekly) on type 2 diabetic patients awaiting for bariatric surgery. DEXBASU study
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Dapagliflozin (Primary) ; Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DEXBASU study
- 11 Aug 2017 New trial record